ATC Group: C03CA02 Bumetanide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C03CA02 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C03 Diuretics
3 C03C High-ceiling diuretics
4 C03CA Sulfonamides, plain
5 C03CA02 Bumetanide

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 1 mg
PAREN - Parenteral 1 mg

Active ingredients in C03CA02

Active Ingredient Description
Bumetanide

Bumetanide is a potent loop diuretic with a rapid onset and a short duration of action. The primary site of action is the ascending limb of the loop of Henle where it exerts inhibiting effects on electrolyte reabsorption, causing its diuretic and natriuretic action.

Related product monographs

Title Information Source Document Type  
BUMETANIDE Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
BURINEX Tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Brazil (BR)

Canada (CA)

Ecuador (EC)

France (FR)

Ireland (IE)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.